Category: Fellows Posters
Purpose: Real-world data (RWD) is a source of information collected from the post marketing space to support the use of medications, monitor safety and help providers make clinical decisions. RWD is captured through the use of electronic health records, insurance claims databases or wearable devices. The introduction of RWD can directly impact patient care because it provides an opportunity to assess the outcomes and measure the effectiveness of drugs causing an increased need to optimize healthcare. The purpose of this study was to determine the accessibility of real-world information from pharmaceutical companies by evaluating the company’s medical information website.
Methods: There are 29 pharmaceutical member companies associated with PhactMI that were evaluated for this study. This study is independent of the PhactMI Organization. Each company’s name was searched on Google along with the terms “medical information” to identify the medical information web page. The medical information website was searched for any content about RWD. If a separate medical information website was not available, that company was deemed as having 0 links on the medical information website. From the companies that had a specific medical information website, a search of the terms “real world” was conducted. The number of results were categorized as either 0, up to and including 10, or greater than 10 total real-world links. If the “real world” search was only possible when a product was specified, then the company’s real-world information accessibility was deemed as “not readily available” due to the extensive search process that would be required of the products in each company’s portfolio.
Results: Of the 29 companies, 23 had specific medical information websites (79.3%). Of the 23 companies with medical information websites, 16 (69.6%) companies could only be searched if a product was specified, 4 (17.4%) companies had no ability to search at all and 3 (13%) companies were able to be searched for the terms “real world”. Of those 3 companies, only 2 companies had RWD information readily available on the medical information website with greater than 10 links available, while 1 company had zero search results. The successful search results included published articles analyzing real-world effectiveness using patient disease registries, scientific response documents titled real-world evidence in a specific drug, or press-releases that outlined drugs that were approved for a new indication due to RWD. Three companies were acquired this past year, which might have played a role in the decreased the accessibility to medical information. Two of the companies acquired did not have a specific medical information websites, and the third company was only able to be searched if a product was specified.
Conclusion: RWD is continuously generated through the increasing availability of electronic health records, claims databases, disease and patient registries, and digital wearables for patients. Medical information teams play a critical role for pharmaceutical companies to provide unbiased and scientifically balanced information, yet there is a gap in the real-world information availability on medical information websites. The search capabilities are also limited, which makes accessing information more difficult. RWD derived from medical information websites can impact a health care professional’s clinical decision and provide hopes for a better outcome.